These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Europe's sweeping chemical law puts medicines in peril. Keim B Nat Med; 2007 Jan; 13(1):4. PubMed ID: 17297677 [No Abstract] [Full Text] [Related]
26. Synthetic peptide API manufacturing: A mini review of current perspectives for peptide manufacturing. Rasmussen JH Bioorg Med Chem; 2018 Jun; 26(10):2914-2918. PubMed ID: 29735426 [No Abstract] [Full Text] [Related]
27. Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001-2011). Wang J; Sánchez-Roselló M; Aceña JL; del Pozo C; Sorochinsky AE; Fustero S; Soloshonok VA; Liu H Chem Rev; 2014 Feb; 114(4):2432-506. PubMed ID: 24299176 [No Abstract] [Full Text] [Related]
28. Continuous processes for the production of pharmaceutical intermediates and active pharmaceutical ingredients. LaPorte TL; Wang C Curr Opin Drug Discov Devel; 2007 Nov; 10(6):738-45. PubMed ID: 17987525 [TBL] [Abstract][Full Text] [Related]
29. Preface of EuPAT 7 Special Issue - Inventing Tomorrow's Development and Manufacturing. Rantanen J; Khinast J Eur J Pharm Sci; 2016 Jul; 90():1. PubMed ID: 27324754 [No Abstract] [Full Text] [Related]
30. Drug discovery: the leading edge. Chapman T Nature; 2004 Jul; 430(6995):109-15. PubMed ID: 15229608 [No Abstract] [Full Text] [Related]
31. Synthetic approaches to the 2012 new drugs. Ding HX; Leverett CA; Kyne RE; Liu KK; Sakya SM; Flick AC; O'Donnell CJ Bioorg Med Chem; 2014 Apr; 22(7):2005-32. PubMed ID: 24629448 [TBL] [Abstract][Full Text] [Related]
32. Synthetic approaches to the 2010 new drugs. Liu KK; Sakya SM; O'Donnell CJ; Flick AC; Ding HX Bioorg Med Chem; 2012 Feb; 20(3):1155-74. PubMed ID: 22261026 [TBL] [Abstract][Full Text] [Related]
33. Synthetic approaches to the 2013 new drugs. Ding HX; Leverett CA; Kyne RE; Liu KK; Fink SJ; Flick AC; O'Donnell CJ Bioorg Med Chem; 2015 May; 23(9):1895-922. PubMed ID: 25797159 [TBL] [Abstract][Full Text] [Related]
34. A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States. Miller CP; Ullrich JW Chirality; 2008 Jun; 20(6):762-70. PubMed ID: 18200591 [TBL] [Abstract][Full Text] [Related]
35. Continuous flow synthesis. A pharma perspective. Malet-Sanz L; Susanne F J Med Chem; 2012 May; 55(9):4062-98. PubMed ID: 22283413 [No Abstract] [Full Text] [Related]
36. Lessons from natural molecules. Clardy J; Walsh C Nature; 2004 Dec; 432(7019):829-37. PubMed ID: 15602548 [TBL] [Abstract][Full Text] [Related]
37. Microreactors for drug discovery: the importance of integrating chemical synthesis with real-time analytical detection. Watts P Anal Bioanal Chem; 2005 Jun; 382(4):865-7. PubMed ID: 15800761 [No Abstract] [Full Text] [Related]
38. Chemical and Pharmaceutical Structure Analysis 2010: From Data to Biology: Analytical Measurements to Drive Pharmaceutical R&D. Needham S; Lee M; Shipkova P Bioanalysis; 2011 Feb; 3(4):359-62. PubMed ID: 21338255 [No Abstract] [Full Text] [Related]
39. [The structure and development of the Danish pharmaceutical industry]. Pyndt PE Tidsskr Tandlaeger; 1985 Dec; (6):252-3. PubMed ID: 3869369 [No Abstract] [Full Text] [Related]
40. Non-regioselective functionalization: an underestimate chemical diversity generator in medicinal chemistry. Guariento S; Biagetti M; Ronchi P Future Med Chem; 2021 Apr; 13(7):595-599. PubMed ID: 33657835 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]